BR112022019241A2 - Agentes de rnai para inibição da expressão de pnpla3, composições farmacêuticas dos mesmos e métodos de uso - Google Patents
Agentes de rnai para inibição da expressão de pnpla3, composições farmacêuticas dos mesmos e métodos de usoInfo
- Publication number
- BR112022019241A2 BR112022019241A2 BR112022019241A BR112022019241A BR112022019241A2 BR 112022019241 A2 BR112022019241 A2 BR 112022019241A2 BR 112022019241 A BR112022019241 A BR 112022019241A BR 112022019241 A BR112022019241 A BR 112022019241A BR 112022019241 A2 BR112022019241 A2 BR 112022019241A2
- Authority
- BR
- Brazil
- Prior art keywords
- rnai agents
- pnpla3
- methods
- pharmaceutical compositions
- alcoholic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01004—Phospholipase A2 (3.1.1.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/331—Universal or degenerate base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3535—Nitrogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Abstract
AGENTES DE RNAI PARA INIBIÇÃO DA EXPRESSÃO DE PNPLA3, COMPOSIÇÕES FARMACÊUTICAS DOS MESMOS E MÉTODOS DE USO. A presente invenção refere-se a agentes de RNAi, por exemplo, agentes de RNAi de fita dupla, capazes de inibir a expressão gênica do domínio de fosfolipase tipo patatina contendo proteína 3 (PNPLA3). Também são descritas composições farmacêuticas que incluem agentes de RNAi de PNPLA3 e métodos de uso dos mesmos. Os agentes de RNAi de PNPLA3 descritos na presente invenção podem ser conjugados com ligantes de direcionamento para facilitar a liberação para as células, incluindo os hepatócitos. A liberação dos agentes de RNAi de PNPLA3 in vivo fornece a inibição da expressão do gene PNPLA3. Os agentes de RNAi podem ser usados em métodos de tratamento de doenças e distúrbios relacionados a PNPLA3, incluindo doença hepática gordurosa não alcoólica (DHGNA), esteato-hepatite não alcoólica (EHNA), fibrose hepática e doenças hepáticas alcoólicas ou não alcoólicas, incluindo cirrose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063000137P | 2020-03-26 | 2020-03-26 | |
PCT/US2021/024299 WO2021195467A2 (en) | 2020-03-26 | 2021-03-26 | RNAi AGENTS FOR INHIBITING EXPRESSION OF PNPLA3, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022019241A2 true BR112022019241A2 (pt) | 2022-11-16 |
Family
ID=75540055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022019241A BR112022019241A2 (pt) | 2020-03-26 | 2021-03-26 | Agentes de rnai para inibição da expressão de pnpla3, composições farmacêuticas dos mesmos e métodos de uso |
Country Status (20)
Country | Link |
---|---|
US (1) | US20210301294A1 (pt) |
EP (1) | EP4125932A2 (pt) |
JP (1) | JP2023519246A (pt) |
KR (1) | KR20220158011A (pt) |
CN (1) | CN115397436A (pt) |
AR (1) | AR121672A1 (pt) |
AU (1) | AU2021242321A1 (pt) |
BR (1) | BR112022019241A2 (pt) |
CA (1) | CA3176418A1 (pt) |
CL (2) | CL2022002580A1 (pt) |
CO (1) | CO2022013746A2 (pt) |
CR (1) | CR20220532A (pt) |
DO (1) | DOP2022000204A (pt) |
EC (1) | ECSP22075322A (pt) |
IL (1) | IL296718A (pt) |
MX (1) | MX2022011907A (pt) |
PE (1) | PE20230345A1 (pt) |
TW (1) | TW202202153A (pt) |
UY (1) | UY39138A (pt) |
WO (1) | WO2021195467A2 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201901841TA (en) * | 2016-09-02 | 2019-03-28 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
JP2020524485A (ja) | 2017-06-02 | 2020-08-20 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | オリゴヌクレオチド組成物及びその使用方法 |
CN111050806A (zh) | 2017-06-02 | 2020-04-21 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
WO2023196941A1 (en) * | 2022-04-08 | 2023-10-12 | Arrowhead Pharmaceuticals, Inc. | Treatment of a non-alcoholic fatty liver disease |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
CA2365625A1 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of substances to cells |
US8137695B2 (en) | 2006-08-18 | 2012-03-20 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
EA024534B1 (ru) | 2010-02-24 | 2016-09-30 | Эрроухэд Рисерч Корпорейшн | КОНЪЮГИРОВАННАЯ СИСТЕМА ДОСТАВКИ И КОМПОЗИЦИЯ ДЛЯ НАПРАВЛЕННОЙ ДОСТАВКИ МАЛЫХ ИНТЕРФЕРИРУЮЩИХ РНК (миРНК) И СПОСОБ ПОЛУЧЕНИЯ КОМПОЗИЦИИ |
US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
BR112014004585A2 (pt) | 2011-08-26 | 2017-06-13 | Arrowhead Res Corp | polímeros de poli(éster vinílico) para liberação de ácido nucleico in vivo |
US8933047B2 (en) | 2012-04-18 | 2015-01-13 | Arrowhead Madison Inc. | Poly(acrylate) polymers for in vivo nucleic acid delivery |
CA2976445A1 (en) * | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
CA3011946A1 (en) | 2016-03-07 | 2017-09-14 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
US10036024B2 (en) * | 2016-06-03 | 2018-07-31 | Purdue Research Foundation | siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD) |
SG11201901841TA (en) | 2016-09-02 | 2019-03-28 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
CN117701562A (zh) * | 2017-09-14 | 2024-03-15 | 箭头药业股份有限公司 | 用于抑制血管生成素-样3(ANGPTL3)的表达的RNAi剂和组合物以及使用方法 |
UY38003A (es) * | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
-
2021
- 2021-03-26 AR ARP210100762A patent/AR121672A1/es unknown
- 2021-03-26 UY UY0001039138A patent/UY39138A/es unknown
- 2021-03-26 TW TW110111184A patent/TW202202153A/zh unknown
- 2021-03-26 AU AU2021242321A patent/AU2021242321A1/en active Pending
- 2021-03-26 EP EP21719475.2A patent/EP4125932A2/en active Pending
- 2021-03-26 US US17/213,787 patent/US20210301294A1/en active Pending
- 2021-03-26 CR CR20220532A patent/CR20220532A/es unknown
- 2021-03-26 MX MX2022011907A patent/MX2022011907A/es unknown
- 2021-03-26 BR BR112022019241A patent/BR112022019241A2/pt unknown
- 2021-03-26 KR KR1020227036413A patent/KR20220158011A/ko active Search and Examination
- 2021-03-26 JP JP2022557767A patent/JP2023519246A/ja active Pending
- 2021-03-26 CN CN202180024737.5A patent/CN115397436A/zh active Pending
- 2021-03-26 WO PCT/US2021/024299 patent/WO2021195467A2/en active Application Filing
- 2021-03-26 IL IL296718A patent/IL296718A/en unknown
- 2021-03-26 CA CA3176418A patent/CA3176418A1/en active Pending
- 2021-03-26 PE PE2022002098A patent/PE20230345A1/es unknown
-
2022
- 2022-09-23 DO DO2022000204A patent/DOP2022000204A/es unknown
- 2022-09-23 CL CL2022002580A patent/CL2022002580A1/es unknown
- 2022-09-26 EC ECSENADI202275322A patent/ECSP22075322A/es unknown
- 2022-09-26 CO CONC2022/0013746A patent/CO2022013746A2/es unknown
-
2023
- 2023-08-31 CL CL2023002586A patent/CL2023002586A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202202153A (zh) | 2022-01-16 |
JP2023519246A (ja) | 2023-05-10 |
CA3176418A1 (en) | 2021-09-30 |
EP4125932A2 (en) | 2023-02-08 |
CR20220532A (es) | 2022-11-28 |
AU2021242321A1 (en) | 2022-10-06 |
UY39138A (es) | 2021-09-30 |
CL2023002586A1 (es) | 2024-01-26 |
CN115397436A (zh) | 2022-11-25 |
DOP2022000204A (es) | 2023-04-30 |
WO2021195467A2 (en) | 2021-09-30 |
CL2022002580A1 (es) | 2023-03-24 |
PE20230345A1 (es) | 2023-03-01 |
IL296718A (en) | 2022-11-01 |
ECSP22075322A (es) | 2022-10-31 |
US20210301294A1 (en) | 2021-09-30 |
CO2022013746A2 (es) | 2022-10-31 |
WO2021195467A3 (en) | 2021-11-11 |
MX2022011907A (es) | 2023-01-05 |
KR20220158011A (ko) | 2022-11-29 |
AR121672A1 (es) | 2022-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022019241A2 (pt) | Agentes de rnai para inibição da expressão de pnpla3, composições farmacêuticas dos mesmos e métodos de uso | |
CO2021003446A2 (es) | Agentes de arni para inhibir la expresión de 17beta-hsd tipo 13 (hsd17b13), composiciones de dichos agentes, y métodos de uso | |
BR112014010223B8 (pt) | uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica | |
Kang et al. | A FoxO1-dependent, but NRF2-independent induction of heme oxygenase-1 during muscle atrophy | |
BR112019002117A2 (pt) | agente de rnai contra infecção do vírus da hepatite b | |
Hu et al. | Icariin protects against glucocorticoid induced osteoporosis, increases the expression of the bone enhancer DEC1 and modulates the PI3K/Akt/GSK3β/β-catenin integrated signaling pathway | |
Dai et al. | Colistin-induced apoptosis of neuroblastoma-2a cells involves the generation of reactive oxygen species, mitochondrial dysfunction, and autophagy | |
BR112014010228A2 (pt) | inibidores de reciclagem de ácidos biliares para tratamento da doença de fígado e hipercolemia colestática | |
NZ588583A (en) | Novel lipid formulations for nucleic acid delivery | |
Shen et al. | Sphingosine 1-phosphate (S1P) promotes mitochondrial biogenesis in Hep G2 cells by activating Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) | |
BR112014011896A2 (pt) | agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr) | |
BRPI0622054B8 (pt) | composto e composição farmacêutica | |
Li et al. | The chromatin remodeling protein BRG1 regulates APAP-induced liver injury by modulating CYP3A11 transcription in hepatocyte | |
BRPI1009842B8 (pt) | uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas | |
Ma et al. | Post-ischemia mdivi-1 treatment protects against ischemia/reperfusion-induced brain injury in a rat model | |
Xiao et al. | Regulation of carboxylesterase‐2 expression by p53 family proteins and enhanced anti‐cancer activities among 5‐fluorouracil, irinotecan and doxazolidine prodrug | |
AR114739A1 (es) | AGENTES DE ARNi PARA INHIBIR LA EXPRESIÓN DE 17b-HSD TIPO 13 (HSD17B13), COMPOSICIONES DE DICHOS AGENTES, Y MÉTODOS DE USO | |
FR3050112B1 (fr) | Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques | |
BR112014011336A2 (pt) | composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele | |
EA202190800A1 (ru) | РНКи АГЕНТЫ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ 17БЕТА-HSD ТИПА 13 (HSD17B13), ИХ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ | |
Hwang et al. | Chemoprotective effect of insulin-like growth factor I against acetaminophen-induced cell death in Chang liver cells via ERK1/2 activation | |
Yamawaki et al. | Impairment of endothelium-dependent relaxation in the arteries cultured with fetal bovine serum | |
AR127537A1 (es) | Compuestos y métodos para reducir la expresión de psd3 | |
Fan et al. | Modulating endoplasmic reticulum stress attenuates mast cell degranulation | |
Gilham et al. | Bromodomain and extraterminal (BET) protein inhibitor, apabetalone, reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro |